← All trials
NCT05644262
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Dec 9, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Southern CaliforniaLead sponsor
- Alzheimer's Clinical Trial Consortium (ACTC)Collaborator
- Alzheimer's Therapeutic Research InstituteCollaborator
- Alzheimer's Therapeutic Research InstituteStudy director
- Georgetown UniversityOverall official - principal investigator
- Medical University of South CarolinaCollaborator
- National Institute on Aging (NIA)Collaborator
- University of Southern CaliforniaReponsible party - principal investigator
- Alzheimer's Therapeutic Research InstituteOfficial
- University of Southern CaliforniaSponsor investigator
- Georgetown UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.